{"id":"NCT02873936","sponsor":"Gilead Sciences","briefTitle":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-27","primaryCompletion":"2018-03-20","completion":"2018-06-26","firstPosted":"2016-08-22","resultsPosted":"2021-01-15","lastUpdate":"2021-05-13"},"enrollment":449,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Filgotinib","otherNames":["GS-6034"]},{"type":"DRUG","name":"Placebo to match filgotinib","otherNames":[]},{"type":"DRUG","name":"csDMARDs","otherNames":[]}],"arms":[{"label":"Filgotinib 200 mg","type":"EXPERIMENTAL"},{"label":"Filgotinib 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Filgotinib 200 mg","deltaMin":66,"sd":null},{"arm":"Filgotinib 100 mg","deltaMin":57.5,"sd":null},{"arm":"Placebo","deltaMin":31.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":104,"countries":["United States","Argentina","Australia","Belgium","France","Germany","Hungary","Israel","Japan","Mexico","Poland","South Korea","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["31334793","38985247","38057656","37747626","36205910","34980223","33274687"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":147},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Nausea","Bronchitis","Headache"]}}